icotec’s KONG®-TL and the KONG®-C vertebral body replacements received FDA 510(k) clearance in the U.S. and CE Mark approval in Europe.
The devices are made from radiolucent, nonmetallic BlackArmor® material with a 360° osseoconductive Ti-iT® pure titanium coating.
The 360° Ti-iT pure titanium coating, featuring an optimized osseoconductive structure, is designed to support rapid engraftment of bone onto the implant. BlackArmor Carbon/PEEK implant material enables artefact-free imaging and aids in planning, application and follow-up care of radiotherapy for patients with tumors.
“With the imminent market launch of the KONG-TL/C vertebral body replacement systems in Europe and the U.S., we have made significant strides toward achieving this target [of establishing a complete product portfolio that provides patients with improved therapy options],” said Roger Stadler, CEO.
icotec's KONG®-TL and the KONG®-C vertebral body replacements received FDA 510(k) clearance in the U.S. and CE Mark approval in Europe.
The devices are made from radiolucent, nonmetallic BlackArmor® material with a 360° osseoconductive Ti-iT® pure titanium coating.
The 360° Ti-iT pure titanium coating, featuring an optimized osseoconductive...
icotec’s KONG®-TL and the KONG®-C vertebral body replacements received FDA 510(k) clearance in the U.S. and CE Mark approval in Europe.
The devices are made from radiolucent, nonmetallic BlackArmor® material with a 360° osseoconductive Ti-iT® pure titanium coating.
The 360° Ti-iT pure titanium coating, featuring an optimized osseoconductive structure, is designed to support rapid engraftment of bone onto the implant. BlackArmor Carbon/PEEK implant material enables artefact-free imaging and aids in planning, application and follow-up care of radiotherapy for patients with tumors.
“With the imminent market launch of the KONG-TL/C vertebral body replacement systems in Europe and the U.S., we have made significant strides toward achieving this target [of establishing a complete product portfolio that provides patients with improved therapy options],” said Roger Stadler, CEO.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
